These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 31362819)

  • 1. Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity.
    Innis BL; Berlanda Scorza F; Blum JS; Jain VK; Older Aguilar A; Post DJ; Roberts PC; Wairagkar N; White J; Bresee J
    Vaccine; 2019 Aug; 37(35):4823-4829. PubMed ID: 31362819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: Methodologic considerations.
    Innis BL; Scorza FB; Blum JS; Jain VK; Aguilar AO; Post DJ; Roberts PC; Wairagkar N; White J; Bresee J
    Vaccine; 2019 Aug; 37(35):4830-4834. PubMed ID: 31362820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010.
    ; Ampofo WK; Baylor N; Cobey S; Cox NJ; Daves S; Edwards S; Ferguson N; Grohmann G; Hay A; Katz J; Kullabutr K; Lambert L; Levandowski R; Mishra AC; Monto A; Siqueira M; Tashiro M; Waddell AL; Wairagkar N; Wood J; Zambon M; Zhang W
    Influenza Other Respir Viruses; 2012 Mar; 6(2):142-52, e1-5. PubMed ID: 21819547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011.
    Girard MP; Katz JM; Pervikov Y; Hombach J; Tam JS
    Vaccine; 2011 Oct; 29(44):7579-86. PubMed ID: 21856358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.
    Cox NJ; Hickling J; Jones R; Rimmelzwaan GF; Lambert LC; Boslego J; Rudenko L; Yeolekar L; Robertson JS; Hombach J; Ortiz JR
    Vaccine; 2015 Nov; 33(48):6503-10. PubMed ID: 26478203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strengthening the influenza vaccine virus selection and development process: Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014.
    Ampofo WK; Azziz-Baumgartner E; Bashir U; Cox NJ; Fasce R; Giovanni M; Grohmann G; Huang S; Katz J; Mironenko A; Mokhtari-Azad T; Sasono PM; Rahman M; Sawanpanyalert P; Siqueira M; Waddell AL; Waiboci L; Wood J; Zhang W; Ziegler T;
    Vaccine; 2015 Aug; 33(36):4368-82. PubMed ID: 26148877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.
    Poland GA; Fleming DM; Treanor JJ; Maraskovsky E; Luke TC; Ball EM; Poland CM
    Vaccine; 2013 Apr; 31 Suppl 1():A1-20. PubMed ID: 23587330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
    Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Abitay R; Nurpeisova A; Sagymbay A; Koshemetov Z; Stukova M; Buzitskaya Z; Кulmagambetov I; Karabayeva D; Davlyatshin T; Khairullin B
    J Med Virol; 2018 Jan; 90(1):41-49. PubMed ID: 28842994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010.
    Girard MP; Katz J; Pervikov Y; Palkonyay L; Kieny MP
    Vaccine; 2010 Oct; 28(42):6811-20. PubMed ID: 20659520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23-24 August 2016.
    Ortiz JR; Hickling J; Jones R; Donabedian A; Engelhardt OG; Katz JM; Madhi SA; Neuzil KM; Rimmelzwaan GF; Southern J; Spiro DJ; Hombach J
    Vaccine; 2018 Feb; 36(7):932-938. PubMed ID: 29221895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative Strategy for a Quadrivalent Live Attenuated Influenza Virus Vaccine.
    Wan Z; Cardenas Garcia S; Liu J; Santos J; Carnaccini S; Geiger G; Ferreri L; Rajao D; Perez DR
    J Virol; 2018 Nov; 92(21):. PubMed ID: 30135124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.
    Rudenko L; Isakova-Sivak I
    Expert Rev Vaccines; 2015 Mar; 14(3):395-412. PubMed ID: 25555687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, immunogenicity and infectivity of new live attenuated influenza vaccines.
    Isakova-Sivak I; Rudenko L
    Expert Rev Vaccines; 2015; 14(10):1313-29. PubMed ID: 26289975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination against influenza: role and limitations in pandemic intervention plans.
    Rebmann T; Zelicoff A
    Expert Rev Vaccines; 2012 Aug; 11(8):1009-19. PubMed ID: 23002981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
    Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
    Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries.
    Rudenko L; van den Bosch H; Kiseleva I; Mironov A; Naikhin A; Larionova N; Bushmenkov D
    Vaccine; 2011 Jul; 29 Suppl 1():A40-4. PubMed ID: 21684428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.